Title: HOUSE BILL 424
Official Title: HOUSE BILL 424
Number of Sections: 1
Source: versions - Third - Prescription Drug Affordability Board - Authority for Upper Payment Limits (Lowering Prescription Drug Costs for All Marylanders Now Act)
Media Type: application/pdf
Strikethrough Detection: 9 sections found

================================================================================

Section 1:
J1, J5 5lr2044
CF SB 357
By: Delegates Cullison and White Holland, White Holland, Alston, Bagnall,
Bhandari, Guzzone, Hill, S. Johnson, Kaiser, Kerr, Lopez, Martinez,
Pena–Melnyk, Rosenberg, Taveras, Woods, and Woorman
Introduced and read first time: January 16, 2025
Assigned to: Health and Government Operations
Committee Report: Favorable with amendments
House action: Adopted
Read second time: February 19, 2025
CHAPTER ______
1 AN ACT concerning
2 Prescription Drug Affordability Board – Authority for Upper Payment Limits
3 (Lowering Prescription Drug Costs for All Marylanders Now Act)
4 FOR the purpose of requiring the Prescription Drug Affordability Board, under certain
5 circumstances, to establish a process for setting upper payment limits for all
6 purchases and payor reimbursements of prescription drug products in the State that
7 the Board determines have led or will lead to affordability challenges; authorizing
8 the Board to reconsider an upper payment limit for a drug that becomes a current
9 shortage; altering requirements related to the setting of upper payment limits by the
10 Board; requiring the Board to confer with the Maryland Medical Assistance Program
11 before establishing an upper payment limit that applies to the Program; prohibiting
12 the Board from taking certain actions related to upper payment limits; and generally
13 relating to the Prescription Drug Affordability Board.
14 BY repealing and reenacting, with amendments,
15 Article – Health – General
16 Section 21–2C–01, 21–2C–13, and 21–2C–14
17 Annotated Code of Maryland
18 (2023 Replacement Volume and 2024 Supplement)
19 BY repealing and reenacting, without amendments,
20 Article – Health – General
21 Section 21–2C–11(a)
EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.
[Brackets] indicate matter deleted from existing law.
Underlining indicates amendments to bill.
Strike out indicates matter stricken from the bill by amendment or deleted from the law by
amendment. *hb0424*
2 HOUSE BILL 424
1 Annotated Code of Maryland
2 (2023 Replacement Volume and 2024 Supplement)
3 BY repealing
4 Article – Health – General
5 Section 21–2C–11(d) and 21–2C–16
6 Annotated Code of Maryland
7 (2023 Replacement Volume and 2024 Supplement)
8 BY adding to
9 Article – Health – General
10 Section 21–2C–16
11 Annotated Code of Maryland
12 (2023 Replacement Volume and 2024 Supplement)
13 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
14 That the Laws of Maryland read as follows:
15 Article – Health – General
16 21–2C–01.
17 (a) In this subtitle the following words have the meanings indicated.
18 (b) “Biologic” means a drug that is produced or distributed in accordance with a
19 biologics license application approved under 42 C.F.R. § 447.502.
20 (c) “Biosimilar” means a drug that is produced or distributed in accordance with
21 a biologics license application approved under 42 U.S.C. § 262(k)(3).
22 (d) “Board” means the Prescription Drug Affordability Board.
23 (e) (1) “Brand name drug” means a drug that is produced or distributed in
24 accordance with an original new drug application approved under 21 U.S.C. § 355(c).
25 (2) “Brand name drug” does not include an authorized generic as defined
26 by 42 C.F.R. § 447.502.
27 (F) “CURRENT SHORTAGE” MEANS A DRUG:
28 (1) LISTED AS CURRENT ON THE FEDERAL FOOD AND DRUG
29 ADMINISTRATION’S DRUG SHORTAGE DATABASE; OR
30 (2) OTHERWISE DETERMINED BY THE BOARD TO BE IN SHORT
31 SUPPLY IN THE STATE.
HOUSE BILL 424 3
1 [(f)] (G) “Generic drug” means:
2 (1) A retail drug that is marketed or distributed in accordance with an
3 abbreviated new drug application, approved under 21 U.S.C. § 355(j);
4 (2) An authorized generic as defined by 42 C.F.R. § 447.502; or
5 (3) A drug that entered the market before 1962 that was not originally
6 marketed under a new drug application.
7 [(g)] (H) “Manufacturer” means an entity that:
8 (1) (i) Engages in the manufacture of a prescription drug product; or
9 (ii) Enters into a lease with another manufacturer to market and
10 distribute a prescription drug product under the entity’s own name; and
11 (2) Sets or changes the wholesale acquisition cost of the prescription drug
12 product it manufactures or markets.
13 [(h)] (I) “Prescription drug product” means a brand name drug, a generic drug,
14 a biologic, or a biosimilar.
15 [(i)] (J) “Stakeholder Council” means the Prescription Drug Affordability
16 Stakeholder Council.
17 21–2C–11.
18 (a) In this section, “Fund” means the Prescription Drug Affordability Fund.
19 [(d) (1) The Board shall be established using special or general funds, which
20 shall be repaid to the State with the funds from the Fund.
21 (2) If the Board receives funding from the Maryland Health Care
22 Commission under paragraph (1) of this subsection, the Board shall repay the funds to the
23 Commission from the Fund over a 3–year period beginning June 1, 2021.]
24 21–2C–13.
25 (a) If, under § 21–2C–07 of this subtitle, the Board finds that it is in the best
26 interest of the State to establish a process for setting upper payment limits for prescription
27 drug products that it determines have led or will lead to an affordability challenge, the
28 Board, in conjunction with the Stakeholder Council, shall draft a plan of action for
29 implementing the process [that includes the criteria the Board shall use to set upper
30 payment limits] IN ACCORDANCE WITH THE REQUIREMENTS OF THIS SECTION.
4 HOUSE BILL 424
1 (b) The criteria for setting upper payment limits shall include consideration of:
2 (1) The cost of administering the prescription drug product;
3 (2) The cost of delivering the prescription drug product to consumers; [and]
4 (3) THE EFFECT THE UPPER PAYMENT LIMIT WILL HAVE ON
5 PROVIDERS OF 340B DRUGS; AND
6 [(3)] (4) Other relevant administrative costs related to the prescription
7 drug product.
8 [(c) The process for setting upper payment limits shall:
9 (1) Prohibit the application of an upper payment limit for a prescription
10 drug product that is on the federal Food and Drug Administration prescription drug
11 shortage list; and
12 (2) Require the Board to:
13 (i) Monitor the availability of any prescription drug product for
14 which it sets an upper payment limit; and
15 (ii) If there becomes a shortage of the prescription drug product in
16 the State, reconsider or suspend the upper payment limit.]
17 (C) (1) IF THE BOARD PREVIOUSLY SET AN UPPER PAYMENT LIMIT FOR A
18 DRUG THAT BECOMES A CURRENT SHORTAGE, THE BOARD MAY RECONSIDER THE
19 PREVIOUSLY SET UPPER PAYMENT LIMIT.
20 (2) THE BOARD MAY NOT:
21 (I) ESTABLISH A NEW UPPER PAYMENT LIMIT FOR A CURRENT
22 SHORTAGE;
23 (II) ENFORCE AN UPPER PAYMENT LIMIT AGAINST PROVIDER
24 OR PHARMACY REIMBURSEMENT REQUIREMENTS FOR MEDICARE PART C OR PART
25 D PLANS; OR
26 (III) COUNT A PHARMACY DISPENSING FEE TOWARD OR
27 SUBJECT A PHARMACY DISPENSING FEE TO AN UPPER PAYMENT LIMIT.
28 (d) (1) If a plan of action is drafted under subsection (a) of this section, the
29 Board shall submit the plan of action to the Legislative Policy Committee of the General
30 Assembly, in accordance with § 2–1257 of the State Government Article, for its approval.
HOUSE BILL 424 5
1 (2) The Legislative Policy Committee shall have 45 days to approve the
2 plan of action.
3 (3) If the Legislative Policy Committee does not approve the plan of action,
4 the Board shall submit the plan to the Governor and the Attorney General for approval.
5 (4) The Governor and the Attorney General shall have 45 days to approve
6 the plan of action.
7 (5) The Board may not set upper payment limits unless the plan is
8 approved, in accordance with this subsection, by:
9 (i) The Legislative Policy Committee; or
10 (ii) 1. The Governor; and
11 2. The Attorney General.
12 21–2C–14.
13 [(a) If a plan of action is approved under § 21–2C–13(d) of this subtitle] IN
14 ACCORDANCE WITH THE PLAN OF ACTION APPROVED BY THE LEGISLATIVE POLICY
15 COMMITTEE ON OCTOBER 22, 2024, the Board may set upper payment limits for
16 prescription drug products that are:
17 (1) Purchased or paid for by a unit of State or local government or an
18 organization on behalf of a unit of State or local government, including:
19 (i) State or county correctional facilities;
20 (ii) State hospitals; and
21 (iii) Health clinics at State institutions of higher education;
22 (2) Paid for through a health benefit plan on behalf of a unit of State or
23 local government, including a county, bicounty, or municipal employee health benefit plan;
24 or
25 (3) Purchased for or paid for by the Maryland State Medical Assistance
26 Program.
27 [(b) The upper payment limits set under subsection (a) of this section shall:
28 (1) Be for prescription drug products that have led or will lead to an
29 affordability challenge; and
6 HOUSE BILL 424
1 (2) Be set in accordance with the criteria established in regulations
2 adopted by the Board.
3 (c) (1) The Board shall:
4 (i) Monitor the availability of any prescription drug product for
5 which it sets an upper payment limit; and
6 (ii) If there becomes a shortage of the prescription drug product in
7 the State, reconsider whether the upper payment limit should be suspended or altered.
8 (2) An upper payment limit set under subsection (a) of this section may not
9 be applied to a prescription drug product while the prescription drug product is on the
10 federal Food and Drug Administration prescription drug shortage list.]
11 [21–2C–16.
12 On or before December 1, 2026, the Board, in consultation with the Stakeholder
13 Council, shall report to the Senate Finance Committee and the House Health and
14 Government Operations Committee, in accordance with § 2–1257 of the State Government
15 Article, on:
16 (1) The legality, obstacles, and benefits of setting upper payment limits on
17 all purchases and payor reimbursements of prescription drug products in the State; and
18 (2) Recommendations regarding whether the General Assembly should
19 pass legislation to expand the authority of the Board to set upper payment limits to all
20 purchases and payor reimbursements of prescription drug products in the State.]
21 21–2C–16.
22 (A) (1) THE BOARD, IN CONSULTATION WITH THE STAKEHOLDER
23 COUNCIL, SHALL DETERMINE WHETHER, IN ADDITION TO SETTING UPPER PAYMENT
24 LIMITS IN ACCORDANCE WITH § 21–2C–14 OF THIS SUBTITLE, IT IS IN THE BEST
25 INTEREST OF THE STATE FOR THE BOARD TO ESTABLISH A PROCESS FOR SETTING
26 UPPER PAYMENT LIMITS FOR ALL PURCHASES AND PAYOR REIMBURSEMENTS OF
27 PRESCRIPTION DRUG PRODUCTS IN THE STATE THAT THE BOARD DETERMINES
28 HAVE LED OR WILL LEAD TO AN AFFORDABILITY CHALLENGE.
29 (2) WHEN MAKING A DETERMINATION UNDER PARAGRAPH (1) OF
30 THIS SUBSECTION, THE BOARD SHALL CONSIDER, IF APPLICABLE:
31 (I) CONTRACT AND BUDGET DATA PROVIDED TO THE BOARD
32 THAT DEMONSTRATES SAVINGS TO THE STATE OR LOCAL GOVERNMENTS AS A
33 RESULT OF UPPER PAYMENT LIMITS SET IN ACCORDANCE WITH § 21–2C–14 OF THIS
34 SUBTITLE;
HOUSE BILL 424 7
1 (II) SUCCESS OF SETTING UPPER PAYMENT LIMITS IN OTHER
2 STATES; AND
3 (III) EXPECTED SAVINGS FROM MEDICARE MAXIMUM FAIR
4 PRICES SET BY THE CENTERS FOR MEDICARE AND MEDICAID SERVICES.
5 (B) (1) IF THE BOARD MAKES AN AFFIRMATIVE DETERMINATION UNDER
6 SUBSECTION (A) OF THIS SECTION, THE BOARD, IN CONSULTATION WITH THE
7 STAKEHOLDER COUNCIL, SHALL ESTABLISH A PROCESS FOR SETTING UPPER
8 PAYMENT LIMITS FOR ALL PURCHASES AND PAYOR REIMBURSEMENTS OF
9 PRESCRIPTION DRUG PRODUCTS IN THE STATE THAT THE BOARD DETERMINES
10 HAVE LED OR WILL LEAD TO AN AFFORDABILITY CHALLENGE.
11 (2) THE PROCESS ESTABLISHED UNDER PARAGRAPH (1) OF THIS
12 SUBSECTION SHALL:
13 (I) TO THE EXTENT APPROPRIATE, USE THE PLAN OF ACTION
14 APPROVED UNDER § 21–2C–13(D) OF THIS SUBTITLE; AND
15 (II) OTHERWISE COMPLY WITH THE REQUIREMENTS FOR
16 SETTING UPPER PAYMENT LIMITS ESTABLISHED UNDER THIS SUBTITLE.
17 (3) BEFORE ESTABLISHING AN UPPER PAYMENT LIMIT THAT APPLIES
18 TO THE MARYLAND MEDICAL ASSISTANCE PROGRAM, THE BOARD SHALL CONFER
19 WITH THE MARYLAND MEDICAL ASSISTANCE PROGRAM TO APPROVE THE
20 APPLICATION OF THE UPPER PAYMENT LIMIT BY ASSESSING WHETHER THE
21 PROPOSED UPPER PAYMENT LIMIT WILL:
22 (I) CONFLICT WITH THE MEDICAID DRUG REBATES
23 PROGRAM, THE COVERED OUTPATIENT DRUG RULE (CMS–2345–FC), OR ANY
24 OTHER FEDERAL REQUIREMENTS AS APPLICABLE; AND
25 (II) REQUIRE ADDITIONAL FUNDING TO BE ALLOCATED TO THE
26 MARYLAND MEDICAL ASSISTANCE PROGRAM BUDGET.
27 SECTION 2. AND BE IT FURTHER ENACTED, That the Laws of Maryland read
28 as follows:
29 Article – Health – General
30 21–2C–16.
31 (C) (1) IF SUBJECT TO PARAGRAPH (2) OF THIS SUBSECTION, IF THE
32 BOARD ESTABLISHES A PROCESS UNDER SUBSECTION (B) OF THIS SECTION, THE
8 HOUSE BILL 424
1 BOARD SHALL SET UPPER PAYMENT LIMITS FOR ALL PURCHASES AND PAYOR
2 REIMBURSEMENTS OF PRESCRIPTION DRUG PRODUCTS IN THE STATE IN
3 ACCORDANCE WITH THE PROCESS.
4 (2) THIS SUBSECTION DOES NOT APPLY WITH RESPECT TO:
5 (I) PAYOR REIMBURSEMENTS UNDER MEDICARE PART C AND
6 D PLANS;
7 (II) PURCHASES UNDER THE FEDERAL 340B DRUG PRICING
8 PROGRAM; AND
9 (III) PURCHASES AND PAYOR REIMBURSEMENTS UNDER
10 FEDERAL PROGRAMS THAT ARE PREEMPTED BY FEDERAL LAW INCLUDING:
11 1. THE DEPARTMENT OF DEFENSE;
12 2. THE DEPARTMENT OF VETERANS AFFAIRS;
13 3. THE PUBLIC HEALTH SERVICE;
14 4. THE UNITED STATES COAST GUARD;
15 5. TRICARE;
16 6. THE FEDERAL EMPLOYEES HEALTH BENEFIT PLAN;
17 AND
18 7. ANY OTHER EXCLUSIVE FEDERAL PROGRAM AS
19 APPLICABLE.
20 SECTION 3. AND BE IT FURTHER ENACTED, That:
21 (a) Section 2 of this Act is contingent on the Prescription Drug Affordability Board
22 setting upper payment limits on two prescription drugs in accordance with § 21–2C–14 of
23 the Health – General Article, as enacted by Section 1 of this Act, and each upper payment
24 limit being in effect for 1 year.
25 (b) Within 5 days after the conditions described in subsection (a) of this section
26 are met, the Prescription Drug Affordability Board shall notify the Department of
27 Legislative Services.
28 (c) If notice is received by the Department of Legislative Services in accordance
29 with subsection (b) of this section on or before September 31 September 30, 2030, Section 2
HOUSE BILL 424 9
1 of this Act shall take effect on the date the notice is received by the Department of
2 Legislative Services.
3 (d) If notice is not received by the Department of Legislative Services on or before
4 December 31 September 30, 2030, Section 2 of this Act, with no further action required by
5 the General Assembly, shall be null and void.
6 SECTION 4. AND BE IT FURTHER ENACTED, That, subject to Section 3 of this
7 Act, this Act shall take effect October 1, 2025.
Approved:
________________________________________________________________________________
Governor.
________________________________________________________________________________
Speaker of the House of Delegates.
________________________________________________________________________________
President of the Senate.
[DELETED: :CA      5   C D C a W W A B G H S K K L M A P ( F c t e a p f s u p l f a p t t s B b t r B  A S  A  ( B  A S]
[DELETED:  H   A  ( B  A S  A  ( B  A S  A  (  S T A 2  ( I  ( “ b  ( “ a  ( “  ( ( “ a   ( “ b ) “C”:UE    LF A C O T F O A R’DSD;NS R H AE    O D B T O T B I S T.]
[DELETED: H 3  () “](   ( A a   ( A   ( A m  () “](   ( ( E    ( E d   ( S p  () “]( a  () “ C m t P D A]( S 2  ( I  ( ( T s   ( I t B r f f t M H C C C. 2  ( I i d B i c w t S C s d a p o a f i t p t i t c t B s u t s u ps.]
[DELETED:  H   ( T   ( T   ( T ad    E T U P L W H O  S B;   () O]( d  ( T   ( P d p t i o t f F a D A p d s   ( R    ( M t a o a p d p f w    ( I t. ) ( IF OE  O   TB: O   ) SE   ) IN E A   APC;S    ) IO A P D F T O  ( ( I B A]
[DELETED: H 5   ( T p   ( I t   ( T t   ( T B m n s u p l u t p i a    ( T    ( 1 T     2 T 2  ( I a p o a i a u § 2 o t s]N E OO2,2 O C  , t B m s u p l f p   ( P o p f b a u o S o l g o a o    ( S    ( S    ( H   ( P l o   ( P P  ( T   ( B f p d p t h l o w l t a a]
[DELETED:  H    ( B s i a w t c e i r a  ( ( T    ( M t a o a p d p f w    ( I t   ( A b f. 2  O C s r t t S F C a t H H a G A   ( T a   ( R r w t G A s p p. ) ( TB,H OD I C W T T,L R    E 24 T O D P I T T T T O D   W( M A D U P  ON  OR B,:   ) CO O D S T T T O L G A A   2]
[DELETED: H 7   ) IU U IS    ) EMMIX S F E A ACMMS. E E E E ) ( IF O A O T SN T OD I C W T),BC OL S E A P F S U L F A P A P R O D P I T T T T O D   T( P E U P  O T   ) TOE   D E 2();   ) IT C W T R F ()  A E S RM  OMAP, T A E S R T A TMA O T U P L B A W T     )CMDO W T E R E,CODR(M T O U R U  O AE      )IEMAP E S R    S a A 2  ) ()IS()F U T P  O T SN I T() B N ]
[DELETED:  H  S S U P L F ALP A P  O P D P I T T IS  ()T      )PMPA E A  PL     )P3BDIU U T F  R RM      )IU A P R U       .TDD E E      .TDVA E E F      .TPHS U E E      .TUSCG N T O U      .T     .TFEHBP E M E E LN      . O E F P A    S  ( S s t l  ( W a m t P D A B s n t D o L  ( I w]
[DELETED: H 9 o t A s t e o t d t n i r b t D o L  ( I D t  S A          G               ]


================================================================================

Raw Text:
HOUSE BILL 424
J1, J5 5lr2044
CF SB 357
By: Delegates Cullison and White Holland, White Holland, Alston, Bagnall,
Bhandari, Guzzone, Hill, S. Johnson, Kaiser, Kerr, Lopez, Martinez,
Pena–Melnyk, Rosenberg, Taveras, Woods, and Woorman
Introduced and read first time: January 16, 2025
Assigned to: Health and Government Operations
Committee Report: Favorable with amendments
House action: Adopted
Read second time: February 19, 2025
CHAPTER ______
1 AN ACT concerning
2 Prescription Drug Affordability Board – Authority for Upper Payment Limits
3 (Lowering Prescription Drug Costs for All Marylanders Now Act)
4 FOR the purpose of requiring the Prescription Drug Affordability Board, under certain
5 circumstances, to establish a process for setting upper payment limits for all
6 purchases and payor reimbursements of prescription drug products in the State that
7 the Board determines have led or will lead to affordability challenges; authorizing
8 the Board to reconsider an upper payment limit for a drug that becomes a current
9 shortage; altering requirements related to the setting of upper payment limits by the
10 Board; requiring the Board to confer with the Maryland Medical Assistance Program
11 before establishing an upper payment limit that applies to the Program; prohibiting
12 the Board from taking certain actions related to upper payment limits; and generally
13 relating to the Prescription Drug Affordability Board.
14 BY repealing and reenacting, with amendments,
15 Article – Health – General
16 Section 21–2C–01, 21–2C–13, and 21–2C–14
17 Annotated Code of Maryland
18 (2023 Replacement Volume and 2024 Supplement)
19 BY repealing and reenacting, without amendments,
20 Article – Health – General
21 Section 21–2C–11(a)
EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.
[Brackets] indicate matter deleted from existing law.
Underlining indicates amendments to bill.
Strike out indicates matter stricken from the bill by amendment or deleted from the law by
amendment. *hb0424*

2 HOUSE BILL 424
1 Annotated Code of Maryland
2 (2023 Replacement Volume and 2024 Supplement)
3 BY repealing
4 Article – Health – General
5 Section 21–2C–11(d) and 21–2C–16
6 Annotated Code of Maryland
7 (2023 Replacement Volume and 2024 Supplement)
8 BY adding to
9 Article – Health – General
10 Section 21–2C–16
11 Annotated Code of Maryland
12 (2023 Replacement Volume and 2024 Supplement)
13 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
14 That the Laws of Maryland read as follows:
15 Article – Health – General
16 21–2C–01.
17 (a) In this subtitle the following words have the meanings indicated.
18 (b) “Biologic” means a drug that is produced or distributed in accordance with a
19 biologics license application approved under 42 C.F.R. § 447.502.
20 (c) “Biosimilar” means a drug that is produced or distributed in accordance with
21 a biologics license application approved under 42 U.S.C. § 262(k)(3).
22 (d) “Board” means the Prescription Drug Affordability Board.
23 (e) (1) “Brand name drug” means a drug that is produced or distributed in
24 accordance with an original new drug application approved under 21 U.S.C. § 355(c).
25 (2) “Brand name drug” does not include an authorized generic as defined
26 by 42 C.F.R. § 447.502.
27 (F) “CURRENT SHORTAGE” MEANS A DRUG:
28 (1) LISTED AS CURRENT ON THE FEDERAL FOOD AND DRUG
29 ADMINISTRATION’S DRUG SHORTAGE DATABASE; OR
30 (2) OTHERWISE DETERMINED BY THE BOARD TO BE IN SHORT
31 SUPPLY IN THE STATE.

HOUSE BILL 424 3
1 [(f)] (G) “Generic drug” means:
2 (1) A retail drug that is marketed or distributed in accordance with an
3 abbreviated new drug application, approved under 21 U.S.C. § 355(j);
4 (2) An authorized generic as defined by 42 C.F.R. § 447.502; or
5 (3) A drug that entered the market before 1962 that was not originally
6 marketed under a new drug application.
7 [(g)] (H) “Manufacturer” means an entity that:
8 (1) (i) Engages in the manufacture of a prescription drug product; or
9 (ii) Enters into a lease with another manufacturer to market and
10 distribute a prescription drug product under the entity’s own name; and
11 (2) Sets or changes the wholesale acquisition cost of the prescription drug
12 product it manufactures or markets.
13 [(h)] (I) “Prescription drug product” means a brand name drug, a generic drug,
14 a biologic, or a biosimilar.
15 [(i)] (J) “Stakeholder Council” means the Prescription Drug Affordability
16 Stakeholder Council.
17 21–2C–11.
18 (a) In this section, “Fund” means the Prescription Drug Affordability Fund.
19 [(d) (1) The Board shall be established using special or general funds, which
20 shall be repaid to the State with the funds from the Fund.
21 (2) If the Board receives funding from the Maryland Health Care
22 Commission under paragraph (1) of this subsection, the Board shall repay the funds to the
23 Commission from the Fund over a 3–year period beginning June 1, 2021.]
24 21–2C–13.
25 (a) If, under § 21–2C–07 of this subtitle, the Board finds that it is in the best
26 interest of the State to establish a process for setting upper payment limits for prescription
27 drug products that it determines have led or will lead to an affordability challenge, the
28 Board, in conjunction with the Stakeholder Council, shall draft a plan of action for
29 implementing the process [that includes the criteria the Board shall use to set upper
30 payment limits] IN ACCORDANCE WITH THE REQUIREMENTS OF THIS SECTION.

4 HOUSE BILL 424
1 (b) The criteria for setting upper payment limits shall include consideration of:
2 (1) The cost of administering the prescription drug product;
3 (2) The cost of delivering the prescription drug product to consumers; [and]
4 (3) THE EFFECT THE UPPER PAYMENT LIMIT WILL HAVE ON
5 PROVIDERS OF 340B DRUGS; AND
6 [(3)] (4) Other relevant administrative costs related to the prescription
7 drug product.
8 [(c) The process for setting upper payment limits shall:
9 (1) Prohibit the application of an upper payment limit for a prescription
10 drug product that is on the federal Food and Drug Administration prescription drug
11 shortage list; and
12 (2) Require the Board to:
13 (i) Monitor the availability of any prescription drug product for
14 which it sets an upper payment limit; and
15 (ii) If there becomes a shortage of the prescription drug product in
16 the State, reconsider or suspend the upper payment limit.]
17 (C) (1) IF THE BOARD PREVIOUSLY SET AN UPPER PAYMENT LIMIT FOR A
18 DRUG THAT BECOMES A CURRENT SHORTAGE, THE BOARD MAY RECONSIDER THE
19 PREVIOUSLY SET UPPER PAYMENT LIMIT.
20 (2) THE BOARD MAY NOT:
21 (I) ESTABLISH A NEW UPPER PAYMENT LIMIT FOR A CURRENT
22 SHORTAGE;
23 (II) ENFORCE AN UPPER PAYMENT LIMIT AGAINST PROVIDER
24 OR PHARMACY REIMBURSEMENT REQUIREMENTS FOR MEDICARE PART C OR PART
25 D PLANS; OR
26 (III) COUNT A PHARMACY DISPENSING FEE TOWARD OR
27 SUBJECT A PHARMACY DISPENSING FEE TO AN UPPER PAYMENT LIMIT.
28 (d) (1) If a plan of action is drafted under subsection (a) of this section, the
29 Board shall submit the plan of action to the Legislative Policy Committee of the General
30 Assembly, in accordance with § 2–1257 of the State Government Article, for its approval.

HOUSE BILL 424 5
1 (2) The Legislative Policy Committee shall have 45 days to approve the
2 plan of action.
3 (3) If the Legislative Policy Committee does not approve the plan of action,
4 the Board shall submit the plan to the Governor and the Attorney General for approval.
5 (4) The Governor and the Attorney General shall have 45 days to approve
6 the plan of action.
7 (5) The Board may not set upper payment limits unless the plan is
8 approved, in accordance with this subsection, by:
9 (i) The Legislative Policy Committee; or
10 (ii) 1. The Governor; and
11 2. The Attorney General.
12 21–2C–14.
13 [(a) If a plan of action is approved under § 21–2C–13(d) of this subtitle] IN
14 ACCORDANCE WITH THE PLAN OF ACTION APPROVED BY THE LEGISLATIVE POLICY
15 COMMITTEE ON OCTOBER 22, 2024, the Board may set upper payment limits for
16 prescription drug products that are:
17 (1) Purchased or paid for by a unit of State or local government or an
18 organization on behalf of a unit of State or local government, including:
19 (i) State or county correctional facilities;
20 (ii) State hospitals; and
21 (iii) Health clinics at State institutions of higher education;
22 (2) Paid for through a health benefit plan on behalf of a unit of State or
23 local government, including a county, bicounty, or municipal employee health benefit plan;
24 or
25 (3) Purchased for or paid for by the Maryland State Medical Assistance
26 Program.
27 [(b) The upper payment limits set under subsection (a) of this section shall:
28 (1) Be for prescription drug products that have led or will lead to an
29 affordability challenge; and

6 HOUSE BILL 424
1 (2) Be set in accordance with the criteria established in regulations
2 adopted by the Board.
3 (c) (1) The Board shall:
4 (i) Monitor the availability of any prescription drug product for
5 which it sets an upper payment limit; and
6 (ii) If there becomes a shortage of the prescription drug product in
7 the State, reconsider whether the upper payment limit should be suspended or altered.
8 (2) An upper payment limit set under subsection (a) of this section may not
9 be applied to a prescription drug product while the prescription drug product is on the
10 federal Food and Drug Administration prescription drug shortage list.]
11 [21–2C–16.
12 On or before December 1, 2026, the Board, in consultation with the Stakeholder
13 Council, shall report to the Senate Finance Committee and the House Health and
14 Government Operations Committee, in accordance with § 2–1257 of the State Government
15 Article, on:
16 (1) The legality, obstacles, and benefits of setting upper payment limits on
17 all purchases and payor reimbursements of prescription drug products in the State; and
18 (2) Recommendations regarding whether the General Assembly should
19 pass legislation to expand the authority of the Board to set upper payment limits to all
20 purchases and payor reimbursements of prescription drug products in the State.]
21 21–2C–16.
22 (A) (1) THE BOARD, IN CONSULTATION WITH THE STAKEHOLDER
23 COUNCIL, SHALL DETERMINE WHETHER, IN ADDITION TO SETTING UPPER PAYMENT
24 LIMITS IN ACCORDANCE WITH § 21–2C–14 OF THIS SUBTITLE, IT IS IN THE BEST
25 INTEREST OF THE STATE FOR THE BOARD TO ESTABLISH A PROCESS FOR SETTING
26 UPPER PAYMENT LIMITS FOR ALL PURCHASES AND PAYOR REIMBURSEMENTS OF
27 PRESCRIPTION DRUG PRODUCTS IN THE STATE THAT THE BOARD DETERMINES
28 HAVE LED OR WILL LEAD TO AN AFFORDABILITY CHALLENGE.
29 (2) WHEN MAKING A DETERMINATION UNDER PARAGRAPH (1) OF
30 THIS SUBSECTION, THE BOARD SHALL CONSIDER, IF APPLICABLE:
31 (I) CONTRACT AND BUDGET DATA PROVIDED TO THE BOARD
32 THAT DEMONSTRATES SAVINGS TO THE STATE OR LOCAL GOVERNMENTS AS A
33 RESULT OF UPPER PAYMENT LIMITS SET IN ACCORDANCE WITH § 21–2C–14 OF THIS
34 SUBTITLE;

HOUSE BILL 424 7
1 (II) SUCCESS OF SETTING UPPER PAYMENT LIMITS IN OTHER
2 STATES; AND
3 (III) EXPECTED SAVINGS FROM MEDICARE MAXIMUM FAIR
4 PRICES SET BY THE CENTERS FOR MEDICARE AND MEDICAID SERVICES.
5 (B) (1) IF THE BOARD MAKES AN AFFIRMATIVE DETERMINATION UNDER
6 SUBSECTION (A) OF THIS SECTION, THE BOARD, IN CONSULTATION WITH THE
7 STAKEHOLDER COUNCIL, SHALL ESTABLISH A PROCESS FOR SETTING UPPER
8 PAYMENT LIMITS FOR ALL PURCHASES AND PAYOR REIMBURSEMENTS OF
9 PRESCRIPTION DRUG PRODUCTS IN THE STATE THAT THE BOARD DETERMINES
10 HAVE LED OR WILL LEAD TO AN AFFORDABILITY CHALLENGE.
11 (2) THE PROCESS ESTABLISHED UNDER PARAGRAPH (1) OF THIS
12 SUBSECTION SHALL:
13 (I) TO THE EXTENT APPROPRIATE, USE THE PLAN OF ACTION
14 APPROVED UNDER § 21–2C–13(D) OF THIS SUBTITLE; AND
15 (II) OTHERWISE COMPLY WITH THE REQUIREMENTS FOR
16 SETTING UPPER PAYMENT LIMITS ESTABLISHED UNDER THIS SUBTITLE.
17 (3) BEFORE ESTABLISHING AN UPPER PAYMENT LIMIT THAT APPLIES
18 TO THE MARYLAND MEDICAL ASSISTANCE PROGRAM, THE BOARD SHALL CONFER
19 WITH THE MARYLAND MEDICAL ASSISTANCE PROGRAM TO APPROVE THE
20 APPLICATION OF THE UPPER PAYMENT LIMIT BY ASSESSING WHETHER THE
21 PROPOSED UPPER PAYMENT LIMIT WILL:
22 (I) CONFLICT WITH THE MEDICAID DRUG REBATES
23 PROGRAM, THE COVERED OUTPATIENT DRUG RULE (CMS–2345–FC), OR ANY
24 OTHER FEDERAL REQUIREMENTS AS APPLICABLE; AND
25 (II) REQUIRE ADDITIONAL FUNDING TO BE ALLOCATED TO THE
26 MARYLAND MEDICAL ASSISTANCE PROGRAM BUDGET.
27 SECTION 2. AND BE IT FURTHER ENACTED, That the Laws of Maryland read
28 as follows:
29 Article – Health – General
30 21–2C–16.
31 (C) (1) IF SUBJECT TO PARAGRAPH (2) OF THIS SUBSECTION, IF THE
32 BOARD ESTABLISHES A PROCESS UNDER SUBSECTION (B) OF THIS SECTION, THE

8 HOUSE BILL 424
1 BOARD SHALL SET UPPER PAYMENT LIMITS FOR ALL PURCHASES AND PAYOR
2 REIMBURSEMENTS OF PRESCRIPTION DRUG PRODUCTS IN THE STATE IN
3 ACCORDANCE WITH THE PROCESS.
4 (2) THIS SUBSECTION DOES NOT APPLY WITH RESPECT TO:
5 (I) PAYOR REIMBURSEMENTS UNDER MEDICARE PART C AND
6 D PLANS;
7 (II) PURCHASES UNDER THE FEDERAL 340B DRUG PRICING
8 PROGRAM; AND
9 (III) PURCHASES AND PAYOR REIMBURSEMENTS UNDER
10 FEDERAL PROGRAMS THAT ARE PREEMPTED BY FEDERAL LAW INCLUDING:
11 1. THE DEPARTMENT OF DEFENSE;
12 2. THE DEPARTMENT OF VETERANS AFFAIRS;
13 3. THE PUBLIC HEALTH SERVICE;
14 4. THE UNITED STATES COAST GUARD;
15 5. TRICARE;
16 6. THE FEDERAL EMPLOYEES HEALTH BENEFIT PLAN;
17 AND
18 7. ANY OTHER EXCLUSIVE FEDERAL PROGRAM AS
19 APPLICABLE.
20 SECTION 3. AND BE IT FURTHER ENACTED, That:
21 (a) Section 2 of this Act is contingent on the Prescription Drug Affordability Board
22 setting upper payment limits on two prescription drugs in accordance with § 21–2C–14 of
23 the Health – General Article, as enacted by Section 1 of this Act, and each upper payment
24 limit being in effect for 1 year.
25 (b) Within 5 days after the conditions described in subsection (a) of this section
26 are met, the Prescription Drug Affordability Board shall notify the Department of
27 Legislative Services.
28 (c) If notice is received by the Department of Legislative Services in accordance
29 with subsection (b) of this section on or before September 31 September 30, 2030, Section 2

HOUSE BILL 424 9
1 of this Act shall take effect on the date the notice is received by the Department of
2 Legislative Services.
3 (d) If notice is not received by the Department of Legislative Services on or before
4 December 31 September 30, 2030, Section 2 of this Act, with no further action required by
5 the General Assembly, shall be null and void.
6 SECTION 4. AND BE IT FURTHER ENACTED, That, subject to Section 3 of this
7 Act, this Act shall take effect October 1, 2025.
Approved:
________________________________________________________________________________
Governor.
________________________________________________________________________________
Speaker of the House of Delegates.
________________________________________________________________________________
President of the Senate.

[DELETED: :CA      5   C D C a W W A B G H S K K L M A P ( F c t e a p f s u p l f a p t t s B b t r B  A S  A  ( B  A S]
[DELETED:  H   A  ( B  A S  A  ( B  A S  A  (  S T A 2  ( I  ( “ b  ( “ a  ( “  ( ( “ a   ( “ b ) “C”:UE    LF A C O T F O A R’DSD;NS R H AE    O D B T O T B I S T.]
[DELETED: H 3  () “](   ( A a   ( A   ( A m  () “](   ( ( E    ( E d   ( S p  () “]( a  () “ C m t P D A]( S 2  ( I  ( ( T s   ( I t B r f f t M H C C C. 2  ( I i d B i c w t S C s d a p o a f i t p t i t c t B s u t s u ps.]
[DELETED:  H   ( T   ( T   ( T ad    E T U P L W H O  S B;   () O]( d  ( T   ( P d p t i o t f F a D A p d s   ( R    ( M t a o a p d p f w    ( I t. ) ( IF OE  O   TB: O   ) SE   ) IN E A   APC;S    ) IO A P D F T O  ( ( I B A]
[DELETED: H 5   ( T p   ( I t   ( T t   ( T B m n s u p l u t p i a    ( T    ( 1 T     2 T 2  ( I a p o a i a u § 2 o t s]N E OO2,2 O C  , t B m s u p l f p   ( P o p f b a u o S o l g o a o    ( S    ( S    ( H   ( P l o   ( P P  ( T   ( B f p d p t h l o w l t a a]
[DELETED:  H    ( B s i a w t c e i r a  ( ( T    ( M t a o a p d p f w    ( I t   ( A b f. 2  O C s r t t S F C a t H H a G A   ( T a   ( R r w t G A s p p. ) ( TB,H OD I C W T T,L R    E 24 T O D P I T T T T O D   W( M A D U P  ON  OR B,:   ) CO O D S T T T O L G A A   2]
[DELETED: H 7   ) IU U IS    ) EMMIX S F E A ACMMS. E E E E ) ( IF O A O T SN T OD I C W T),BC OL S E A P F S U L F A P A P R O D P I T T T T O D   T( P E U P  O T   ) TOE   D E 2();   ) IT C W T R F ()  A E S RM  OMAP, T A E S R T A TMA O T U P L B A W T     )CMDO W T E R E,CODR(M T O U R U  O AE      )IEMAP E S R    S a A 2  ) ()IS()F U T P  O T SN I T() B N ]
[DELETED:  H  S S U P L F ALP A P  O P D P I T T IS  ()T      )PMPA E A  PL     )P3BDIU U T F  R RM      )IU A P R U       .TDD E E      .TDVA E E F      .TPHS U E E      .TUSCG N T O U      .T     .TFEHBP E M E E LN      . O E F P A    S  ( S s t l  ( W a m t P D A B s n t D o L  ( I w]
[DELETED: H 9 o t A s t e o t d t n i r b t D o L  ( I D t  S A          G               ]